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1078–5884/00Thrombolysis for Acute Lower Limb Ischaemia—
A Prospective, Randomised, Multicentre Study Comparing
Two Strategies
G. Plate,1* I. Jansson,2 C. Forssell,3 P. Weber4 and S. Oredsson1Departments of Surgery, Central Hospital, 1Helsingborg, 2Eskilstuna, 3Va¨stera˚s, and 4Va¨xjo¨, SwedenObjectives. To test if initial high-dose, pulse-spray thrombolysis improves the early and late outcome of lower limb
ischaemia as compared with low-dose infusion alone.
Design. Prospective randomised multicentre study.
Material and methods. Patients with acute and sub-acute (!30 days) lower limb ischaemia were randomised following
angiography. Group 1 (nZ58) received pulse-spray infusion of recombinant plasminogen activator (rt-PA, 15 mg/h) for 2 h
followed by low-dose infusion if needed. Group 2 (nZ63) were only treated with low-dose infusion (0.5 mg/h) of rt-PA for
48 h. Underlying lesions were corrected if required.
Results. The study was stopped prematurely. Complications were equally frequent in both groups. More than 75% lysis was
accomplished in 78 versus 67% of the patients (pZ0.21). Primary endpoints (re-occlusion, incomplete lysis, life-
threatening complication, amputation, or death) were reached in 24 versus 32% of the patients (pZ0.35). Neither vascular
patency nor clinical parameters differed during the first year, but re-interventions tended to be more frequent (pZ0.040 at 1
month; pZ0.090 at 1 year) and of a greater magnitude (pZ0.028) in group 2.
Conclusions. There was no obvious advantage with initial high-dose thrombolysis, which may be a type-2 error.
A reduction of major re-interventions was recorded.Keywords: Arterial occlusive disease; Acute limb ischaemia; Thrombolytic therapy; Lower extremity; Fibrinolytic agents;
Recombinant tissue plasminogen activator; Adverse effects.Introduction
Acute ischaemia of the lower extremity caused by
arterial embolism or thrombosis of native vessels and
grafts is a serious condition afflicted with substantial
morbidity and mortality. Blaisdell et al.1 and others2,3
have reported amputation and death in 15–30% of
patients treated with anticoagulation therapy or
surgery.
Thrombolysis with intravenous administration of
streptokinase was first described by Tillett et al. in
1955,4 but was initially not very successful and
compromised by considerable haemorrhagic compli-
cations.5–7 These problems have subsequently been
ameliorated by refinements of techniques (intra-
arterial, catheter-directed, and intra-thrombotic drug
delivery) and drugs (urokinase and recombinant tissue
plasminogen activator, rt-PA).3,6–8 Three prospective,
randomised trials thereafter compared low-dose intra-ing author. Gunnar Plate, MD, PhD, Department of
tral Hospital, SE-251 87 Helsingborg, Sweden.
: gunnar.plate@helsingborgslasarett.se
0651+ 10 $35.00/0 q 2005 Elsevier Ltd. All rights reserthrombotic thrombolysis of urokinase or rt-PA with
initial surgical intervention.9–12 The studies demon-
strated a reduction in the magnitude of interventions
required and a better early survival with thrombolysis,
but severe haemorrhages were recorded and recurrent
ischaemia hampered the late clinical outcome.
Reviewers concluded that low-dose, intra-thrombotic
thrombolysis was not conclusively better than surgical
treatment.13
During the beginning of the 1990s, various tech-
niques for initial high-dose delivery of the thrombo-
lytic agent, including forced periodic (e.g. pulse-spray)
infusion, to accelerate lysis of the thrombus were
developed.14–17 Two prospective, randomised studies
comparing conventional low-dose infusion with
different techniques of high-dose thrombolysis
demonstrated contradictory results.18,19
The primary aim of the study was to investigate if
initial high-dose thrombolysis with the pulse-spray
technique improves the outcome of acute and sub-
acute lower limb ischaemia as compared with low-
dose thrombolysis alone.Eur J Vasc Endovasc Surg 31, 651–660 (2006)
doi:10.1016/j.ejvs.2005.11.017, available online at http://www.sciencedirect.com onved.
G. Plate et al.652Material and MethodsSetting
Four Swedish vascular surgical centres at the county
hospitals in Eskilstuna, Helsingborg, Va¨stera˚s, and
Va¨xjo¨ participated. One vascular surgeon and one
interventional radiologist in each centre were respon-
sible for treatment consistency and reporting of data.
Study coordinator was Sven Oredsson, Helsingborg,
where the registry was located. The study was
conducted according to the guidelines for good clinical
practice for research and the declaration of Helsinki.
The Ethical Committees of the universities in Lund,
Go¨teborg, Linko¨ping, and O¨rebro, Sweden approved
the study.Participants
Patients with sudden onset of unilateral lower limb
ischaemiawithin 30 days and angiographic evidence of
thrombo-embolic occlusion distal to the aortic bifur-
cation in whom a guide-wire could be passed at least
5 cm into the thrombus were evaluated for inclusion in
the study. Occlusions of embolic origin and in situ
thromboses of native vessels and vascular grafts were
accepted. All patients that met the clinical inclusion
criteria, but did not have any exclusion criteria
(Table 1), were provided oral and written information
of the study before angiography. In accordancewith the
recommendations of the ethical committees and the
Swedish practice at that time, no written consent was
obtained. All participants provided oral consent.
Objectives
The main objective was to compare high-dose
thrombolysis using pulse-spray technique withTable 1. Exclusion criteria
Major surgery!10 days
Haematuria!10 days
Gastrointestinal bleeding!10 days
Stroke!3 months
Coagulopathy
Pregnancy
Brain tumour
Malignant hypertension
Dacron prosthesis implanted!3 months
Graft infection
Irreversible or profound ischaemia
Contrast allergy
Life-expectancy!30 days
Age!18 years
Non-cooperative patient
Eur J Vasc Endovasc Surg Vol 31, June 2006low-dose thrombolysis in terms of mortality, life-
threatening complications, limb salvage, and require-
ment for re-intervention. The primary hypothesis was
that initial high-dose thrombolysis improves the early
results (numbers and scores of endpoints) as
compared to the conventional low-dose technique.
Secondary objectives were to study the angiographic
degree of lysis, requirement for additional endovas-
cular and surgical re-intervention as well as clinical
and economic outcome. An analysis of subgroups was
intended to find prognostic factors determining out-
come and reported in a later communication.InterventionsAngiography
Contra- or ipsi-lateral puncture of the femoral artery
was performed dependent on the presumed thrombus
location. The proximal and distal thrombus extension
and the peripheral run-off were investigated and
guide-wire passage through the thrombus was
attempted. Introducers (5–6 F) were left in place
during the entire thrombolysis.Study treatment
Group 1: Pulse-spray, high-dose infusion: Recombinant
tissue plasminogen activator (rt-PA, Actilysew,
Boehringer-Ingelheim GmbH, Ingelheim, Germany)
was used as the thrombolytic agent. This was
dissolved in sodium chloride into a solution of
0.33 mg/ml. Forced periodic (pulse-spray) infusion
was administered into the thrombus with a special
infusion pump (Pulse Spray Injectorw PSI-1, Angio
Dynamics, Glen Falls IL, USA) in doses of about
0.13 mg (0.4 ml of the prepared solution) twice per
minute (15 mg/h) using catheters with 10–20 cm
long distal heads with multiple orifices and tip
occluders (Pulse*Sprayw, AngioDynamics Inc, Glen
Falls IL, USA). Pulse-spray infusion was continued
until the lysis was complete, severe complications
occurred, or for the recommended 2 h. Control
angiograms were obtained every 30 min and cath-
eter repositioning was performed as required. The
extent of remaining thrombus was assessed and
complementary low-dose infusion (technique as
described below) was instituted if the lysis was
considered insufficient. Minor remaining thrombi
were accepted if an adequate peripheral blood flow
had been restored.
Group 2: End-hole, low-dose treatment: Rt-PA (Acti-
lysew) was administered into the thrombus using end-
hole catheters.A bolus of 0.25 mg (2.5 ml)was followed
by a continuous infusion of 0.5 mg (5 ml)/h until the
Thrombolysis for Acute Lower Limb Ischaemia 653lysis was complete, severe complications occurred, or
for recommended 48 h. Control angiograms were
obtained every 12 h and catheter repositioning was
performed as required.
Patient monitoring
The heart rate, blood pressure, puncture sites, and
status of the ischaemic limb were checked at least
twice every hour. Blood levels of haemoglobin,
platelets, prothrombin time (PK), and activated partial
thromboplastin time (APTT) were checked every 6 h.
Adjunctive medical therapy
Five thousand units of heparin were administered
intravenously immediately before starting the
thrombolysis. During low-dose thrombolysis, heparin
(600 U/h) was continuously infused via the introducer
using a separate infusion pump adjusting the APTT to
60–120 s. After completing thrombolysis, anticoagula-
tion with low molecular weight heparin was adminis-
tered subcutaneously twice daily for 3 days and the
patients were given oral anticoagulants or antiplatelet
drugs on the discretion of the treating physician.
Adjunctive interventions
Underlying vascular lesions causing the acute throm-
bosis (mainly stenoses exceeding 50% luminal
reduction) were treated with percutaneous translum-
inal angioplasty (PTA) with or without stenting
immediately after termination of thrombolysis. If the
responsible surgeon considered that surgical correc-
tion of the underlying lesion was necessary, these
operations were performed within 1 week.Table 2. Risk index used for stratification
Risk factor Point
Myocardial infarction!6 months ago 10
Myocardial infarctionO6 months ago 5
Frequent angina pectoris 10
Heart failure 10
Aortic valve stenosis 10
Arrhythmia 5
Stroke!6 months ago 10
StrokeO6 months ago 5
AgeO70 years 5
Risk indexZsum of points; low riskZindex!20;
high riskZindexR20.Outcomes
Before the start of the study, primary endpoints were
defined and each was given a specific value according
to an ordinal scale: five pointsZdeath; four pointsZ
life-threatening complication; three pointsZamputa-
tion; two pointsZincomplete lysis requiring immedi-
ate surgical intervention; one pointZre-occlusion
requiring new thrombolysis or surgery. If several
endpoints were reached, only the one with the highest
value was used (endpoint-score).
According to the recommendations of ‘TheWorking
Party on Thrombolysis in the Management of Limb
Ischemia’ and ‘The Society of Interventional Radiology
Technology Assessment Committee’ both published in
2003,20,21 we also assessed (secondary analyses)
separate endpoints: Degree of lysis, patency of the
initially occluded vessel, and clinical outcome inclu-
ding amputation-free survival (major amputations).Comparisons of economic consequences as well as the
number and magnitude of re-interventions performed
are considered as ancillary analyses.
Case record forms were completed by the respon-
sible surgeon and sent to the study centre in
Helsingborg. In order to achieve as correct and
uniform evaluation as possible, all data were validated
and analysed by one single author (G.P.).Sample size
We assumed that 30% of the patients treated with low-
dose infusion would reach a primary endpoint within
30 days and estimated that this would reduce to 20%
using the high-dose technique. To demonstrate this
difference 590 patients are required (powerZ0.80,
pZ0.05). At the time of initiation of the study, 10
centres were involved, each having the intention of
enrolling 30 patients per year, with conclusive results
expected to be available after 2 years.Randomisation
The random allocation sequence was computer
generated, separately for each centre. The sequence
was concealed to all participants. The responsible
vascular surgeon contacted Helsingborg Hospital
switchboard by telephone from the angiography
suite. After receiving patient identification, the oper-
ator immediately provided treatment group allocation
using centre and risk index (low/high risk, Table 2) as
stratification parameters. No blinding of assigned
treatment was possible.Statistical methods
Statistical analysis was performed using SPSS 11.0
(Statistical Package for the Social Sciences, SPSS Inc,
Chicago, IL, USA) and Stata 9.0 (Stata StatisticalEur J Vasc Endovasc Surg Vol 31, June 2006
Table 3. Demographic data
Variable Group 1
(nZ58)
Group 2
(nZ63)
All
(nZ121)
Age (mean; range) 73; 52–89 72; 47–97 72; 47–97
Female sex 24 (41%) 34 (54%) 58 (48%)
Smoking 20 (35%)* 23 (37%)* 43 (36%)*
Diabetes 9 (16%) 11 (18%) 20 (17%)
Heart disease 36 (62%) 40 (64%) 76 (63%)
Hypertension 15 (26%) 28 (44%) 43 (36%)
G. Plate et al.654Software, StataCorp LP, College Station, TX, USA).
Pearson chi-square test was used for 2!2 tables and
the Wilcoxon–Mann–Whitney test (WMW) for ordinal
data. The log rank test was used for life-table analysis
of patency; since only grouped data on times to
occlusion were available, Kaplan–Meier curves would
not be very useful. p-Values!0.05 were considered
statistically significant.Cerebrovascular disease 8 (14%) 15 (24%) 23 (19%)
Hyperlipidaemia 6 (10%)* 10 (16%)* 16 (13%)*
Previous vascular intervention 24 (41%) 30 (48%) 54 (45%)
Risk index (median; range) 7.5; 0–35 5; 0–25 5; 0–35Results
Number of patients.
* Information missing in several patients.Recruitment and patient flow
For various reasons, only four centres went on to
include patients starting in May 1997. The study was
terminated after 3 years when 121 patients had been
included. The study design and flow of patients is
presented in Fig. 1. All patients received the intended
treatment, but thrombolysis was in some cases
extendedbeyond the recommended timedue to clinical
decisions made by the responsible surgeon and
radiologist. All surviving patients were available for
follow-up after 1 month (nZ108) and 1 year (nZ95).Baseline data
The patients’ demographic and clinical data are
presented in Tables 3 and 4. Thirty-four patients (26
versus30%)wereolder than80yearsof age. Separationof
occlusions with embolic origin from in situ thromboses
was not possible, although most cases probably
belonged to the latter group. Thirty-five patients had
occluded grafts (30 with synthetic and five with
autogenous graft material) in an aorto-iliac (8), femoro-
popliteal (22), or tibial (5) position. The proximal level of1 month:       52 patients           56 patients
            (6 dead)             (7 dead)
1year:           46 patients            49 patients
           (12 dead)               (14 dead)
  Complementary
       low-dose
     (38 patients)
Pulse-spray
high-dose
(58 patients)
Endhole
low-dose
(63 patients)
 RANDOMISATION
ANGIOGRAPHY
ARTERIAL OCCLUSION
Fig. 1. Study design and flow of patients.
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angiography (Table 5). Therewere fewer proximal (iliac)
occlusions in group 1 (7%, 95% CIZ0–14%) than in
group 2 (21%, 95%CIZ10–31%). Thereweremore distal
(popliteal and crural) occlusions in group 1 (24%, 95%
CIZ13–35%) than in group 2 (11, 95% CIZ3–19%).
Guide-wire passage through the entire thrombus was
possible in 42/57 patients (74%, 95% CIZ62–85%) in
group 1 and in 30/62 patients (48%, 95% CIZ36–61%)
in group 2. There were no other notable differences
between the groups.Treatment providedGroup 1
Pulse-spray, high-dose thrombolysis was continued
for 120 (40–310) min, with a calculated dose of 30 (10–
75) mg of rt-PA. Complementary low-dose infusion
was given to 38/58 patients (66%) for 18 (1–50) h with
a calculated dose of 9 (0.5–25) mg. The calculated total
dose of rt-PA given was 36 (19–93) mg in group 1. All
numbers are given as median (range).Table 4. Clinical data
Variable Group 1 Group 2 All
Severity of symptoms (nZ58) (nZ63) (nZ121)
Claudication 11 (19%) 7 (11%) 18 (15%)
Rest pain 42 (72%) 50 (79%) 92 (76%)
Tissue loss 5 (9%) 6 (10%) 11 (9%)
Duration of symptoms (nZ58) (nZ63) (nZ121)
!1 day 14 (24%) 15 (24%) 29 (24%)
1–3 days 13 (22%) 15 (24%) 28 (23%)
4–7 days 14 (24%) 18 (29%) 32 (26%)
8–30 days 17 (29%) 15 (24%) 32 (26%)
Muscle weakness (nZ57) (nZ63) (nZ120)
None 34 (60%) 42 (67%) 76 (63%)
Mild 21 (37%) 17 (27%) 38 (32%)
Severe 2 (4%) 4 (6%) 6 (5%)
Ankle/brachial index (nZ56) (nZ62) (nZ118)
Median (range) 0.3 (0–0.8) 0.0 (0–0.8) 0.1 (0–0.8)
Number of patients.
Table 5. Angiographic findings
Variable Group 1 Group 2 All
Proximal occlusion level (nZ58) (nZ63) (nZ121)
Iliac 4 (7%) 13 (21%) 17 (14%)
Femoral 40 (69%) 43 (68%) 83 (69%)
Popliteal or crural 14 (24%) 7 (11%) 21 (17%)
Run-off* (nZ57) (nZ62) (nZ120)
Good 21 (36%) 22 (36%) 43 (36%)
Bad 24 (41%) 20 (32%) 44 (37%)
Very bad 13 (22%) 20 (32%) 33 (28%)
Number of patients.
* Run-off was classified as: goodZ2–3 crural arteries, badZ1
crural artery, or very badZfragments of crural arteries.
Table 7. Endpoints (score), 1 month
Variable Group 1 (nZ58) Group 2 (nZ63)
None (0) 44 (76%) 43 (68%)
Re-occlusion* (1) 2 (3%) 2 (3%)
Incomplete lysis* (2) 2 (3%) 8 (13%)
Amputation (3) 3 (5%) 2 (3%)
Life-threatening
complication (4)
1 (2%) 1 (2%)
Death (5) 6 (10%) 7 (11%)
Number of patients. Endpoint with highest score recorded in each
patient.
* Only if re-intervention (surgery or re-thrombolysis) was
required. WMW, ZZK0.790, pZ0.43.
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Low-dose infusion was administered for 25 (2–60) h
with a calculated dose of 13 (1–30) mg of rt-PA. All
numbers are given as median (range).Adjunctive treatment
Adjunctive medical therapy and interventions per-
formed are described in Table 6. The same principles
were applied in both groups and there was no notable
difference recorded. Underlying vascular lesions were
detected and corrected in 81/121 patients (67% in both
groups).Early outcomesPrimary analysis
After 1 month, 14/58 (24%) of the patients in group 1
and 20/63 (32%) of the patients in group 2 had reached
a primary endpoint (c2Z0.87, 1 d.f., pZ0.35; 95% CI
for difference: K24 to 8%). The endpoint scores
(Table 7) did not differ between the groups (WMW,
ZZK0.79, pZ0.43).20%
25%
Group 1
P=0.094
Secondary analyses
The outcome of each separate endpoint is presented inTable 6. Adjunctive treatment
Variable Group 1 Group 2 All
Medical*
Antiplatelet drugs 28 (56%) 35 (65%) 63 (61%)
Oral anticoagulation 20 (40%) 18 (33%) 38 (37%)
None 2 (4%) 1 (2%) 3 (3%)
Interventions
PTA† 36 (62%) 36 (57%) 72 (60%)
Stenting 2 (3%) 4 (6%) 6 (5%)
Aneurysm exclusion‡ 1 (2%) 1 (2%) 2 (2%)
Endarterectomy§ 0 1 (2%) 1 (1%)
Number of patients.
* Information missing in 17 patients.
† Percutaneous transluminal angioplasty.
‡ Popliteal aneurysms.
§ Outflow in groin.Fig. 2, in which incomplete lysis (aided by adjunctive
procedures) and re-occlusion is recorded even if no
additional intervention was performed. No endpoint
was significantly different when comparing the
groups, although incomplete lysis was recorded in
7/58 patients (12%) in group 1 and in 15/63 patients
(24%) in group 2 (c2Z2.80, 1 d.f., pZ0.094). The 30-day
mortality was 6/58 (10%) and 7/63 (11%) and major
amputations were performed in 4/58 patients (7%)
and 3/63 patients (5%), respectively. The amputation-
free survival was 49/58 patients (85%) and 54/63
patients (86%), respectively. The early clinical results,
which are presented in Table 8, did not differ between
the groups. Non-amputated surviving patients (nZ48
and nZ53) had a median (range) ankle/brachial index
of 0.9 (0–1.4) and 0.9 (0–1.3), respectively. The degree
of lysis, as assessed by angiograms obtained immedi-
ately after completed thrombolysis (unaided by
adjunctive procedures) did not differ between the
groups. More than 75% lysis was accomplished in 45/
58 patients (78%) in group 1 and in 41/61 patients
(67%) in group 2 (c2Z1.60, 1 d.f., pZ0.21).0%
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Fig. 2. Separate endpoints at 1 month. All endpoints
recorded including incomplete lysis and re-occlusion with-
out re-intervention. Lysis was considered incomplete if
sufficient peripheral flow was not accomplished following
thrombolysis aided by adjunctive procedures.
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Table 8. Clinical results
Variable Early Late
Group 1 (nZ57)* Group 2 (nZ62)* All (nZ119) Group 1 (nZ57)* Group 2 (nZ60)* All (nZ117)
No symptoms 35 (61%) 39 (63%) 74 (62%) 34 (60%) 31 (52%) 65 (56%)
Claudication 8 (14%) 4 (7%) 12 (10%) 3 (5%) 3 (5%) 6 (5%)
Rest pain 1 (2%) 3 (5%) 4 (3%) 1 (2%) 1 (2%) 2 (2%)
Tissue loss 4 (7%) 7 (11%) 11 (9%) 2 (4%) 4 (7%) 6 (5%)
Number of patients.
* Symptoms not registered in 1–3 patients.
G. Plate et al.656Late outcomes
Endpoints were now evaluated separately, since some
of these were not designed for late analysis. After 1
year, 12/58 patients (21%) in group 1 and 14/63
patients (22%) in group 2 had died. Seven (12%) and
eight patients (13%), respectively, had been ampu-
tated. The amputation-free survival was 41/58 (71%)
and 43/63 (68%), respectively. There was no difference
in clinical results between the two groups (Table 8).
The non-amputated patients (nZ43 and nZ45) had a
median (range) ankle/brachial index of 0.8 (0–1.3) and
0.9 (0–1.3). Using information from 1 week, 1 month,
and 1 year, with corrections made for the slight
difference in survival, a life-table analysis (log-rank
test) did not show any significant difference in primary
(pZ0.19) or secondary (pZ0.11) patency.Ancillary analyses
Economic analysis (prescribed)
In group 1: Pulse-spray thrombolysis was performed
in the radiology suite in all patients, whereas the
complementary low-dose regimen was given in the
intensive care unit (ICU) in 9/38 patients (24%), in a
recovery room in 27/38 patients (71%), and in an
ordinary ward room in 2/38 patients (5%). In group 2
(informationmissing in one patient): the ICUwas used
in 21/62 (33%), recovery room in 37/62 (59%), and a
ward room in 4/62 (6%). The median number of hours
spent in the ICU and recovery were 2.8 and 8.4,Table 9. Re-interventions
Variable 1 Month
Procedures Group 1 (nZ58) Group 2 (nZ63) A
Thrombolysis 2 0 2
Percutaneous angioplasty 2 2 4
Thrombo-embolectomy 6 4 10
Aorto-iliofemoral bypass 0 1 1
Iliac or femoral TEA* 0 3 3
Femoropopliteal bypass 0 4 4
Femorotibial bypass 0 6 6
Total 10 20 30
Number of procedures.
* Thrombendarterectomy.
Eur J Vasc Endovasc Surg Vol 31, June 2006respectively, in group 1, and to 8.2 and 14.7,
respectively in group 2. Since these figures are based
on calculations and not precise no statistical compari-
son was performed. The mean hospital stay was
5.1 days in group 1 and 6.6 days in group 2 (WMW,
ZZK1.91, pZ0.056). No other economic comparisons
were performed.Analysis of re-interventions (prescribed)
Re-interventions due to incomplete lysis, re-stenosis,
or re-occlusion were performed within 1 month in
7/58 patients (10 procedures) in group 1 and in 17/63
patients (20 procedures) in group 2 (Table 9).
Additional re-interventions were performed from 1
month to 1 year in 7/52 patients (seven procedures) in
group 1 and in 8/56 patients (13 procedures) in group
2. Statistical analysis demonstrated that the number of
patients subjected to re-intervention was lower in
group 1 at 1month (c2Z4.23, 1 d.f., pZ0.040) but not at
1 year (c2Z2.87, 1 d.f., pZ0.090). The number of
procedures performed was also lower in group 1 at 1
month (WMW, ZZK1.97, pZ0.049) but not at 1 year
(ZZK1.74, pZ0.082). The differences at 1month could
not be caused by a difference in observation time
(survival), since the non-surviving patients in group 2
(nZ7) died somewhat earlier than those in group 1
(nZ6).Exploratory analysis
The types of each additional vascular re-intervention
performed are presented in Table 9. Of the 501 Month to 1 year
ll (nZ121) Group 1 (nZ52) Group 2 (nZ56) All (nZ108)
2 2 4
2 3 5
0 0 0
0 1 1
0 1 1
1 4 5
2 2 4
7 13 20
Table 10. Adverse events
Variable Group 1
(nZ58)
Group 2
(nZ63)
All
(nZ121)
Death (!30 days) 6 7 13
Bleeding
Minor 12 7 19
Major 4 8 14
Cardiac 3* 5† 8
Haemorrhagic stroke 2‡ 0 2
Ischaemic stroke 1 1* 2
Peripheral embolisation 10 8 18
Contra-lateral occlusion 1 1 2
Compartmental syndrome 1 1 2
Other§ 1 2 3
Number of events.
* One fatal.
† Four fatal.
‡ Two fatal.
§ Renal failure; septicaemia, allergy.
Thrombolysis for Acute Lower Limb Ischaemia 657procedures performed, 25 were classified as minor (re-
thrombolysis, percutaneous transluminal angioplasty,
or thrombo-embolectomy) and 25 were classified as
major (by-pass or thrombendarterectomy). Three
patients (5%) were subjected to major and 10 (17%)
to minor re-interventions in group 1, whereas 18
patients (27%) were subjected to major and five
patients (8%) to minor re-interventions in group 2
(WMW, ZZK2.19, pZ0.028).Adverse events
All in all 68 adverse events (35 and 33, respectively)
were registered in 55 patients (47 versus 44%) and
presented in Table 10. Most complications consisted of
minor bleeding and peripheral embolisation. Thirteen
events were fatal (10 versus 11%), all occurring in
patients aged above 73 years of age. Thrombolysis was
terminated due to complications in 14 patients (6 and
8, respectively). Bleeding from the puncture site was
quite common (minor oozing was not even recorded
as an adverse event). Three patients in each group
developed gastrointestinal bleeding or haematuria,
but these events were not considered life-threatening.
Fourteen bleeding events required blood transfusion
or surgery and were considered as major. Five of these
major bleedings (3 and 2, respectively) were associated
with the patient’s death. Five of eight cardiac events (2
and 6%, respectively) were fatal. Four of these cardiac
events were associated with bleeding complications.
One ischaemic stroke was recorded in each group,
but only that in group 2 was fatal. Both patients had
chronic atrial fibrillation. In addition, two fatal
cerebral haemorrhages occurred, both in group 1
(4%), creating a total incidence of stroke of 3/58 (5%)
and 1/63 (2%), respectively.Peripheral embolism regularly occurs during
thrombolysis and was registered as an adverse event
in 17 patients. Embolectomy was required in three of
these (1 and 2, respectively) and two led to a major leg
amputation within a month. Two patients (one in each
group) required surgery for thrombotic occlusion at
the puncture site in the contra-lateral groin. One of
these subsequently had a major leg amputation.
Fasciotomy was required in two patients due to
development of a compartmental syndrome following
restitution of peripheral blood flow. Both these limbs
were saved.Discussion
Since this study was started, several publications have
reviewed the role of thrombolytic therapy in the
management of acute arterial ischaemia.21–24 Most of
these conclude that thrombolysis has no obvious
benefit over surgical management. Several reports of
recurrent ischaemia, haemorrhagic complications and
stroke have hampered the enthusiasm with this
treatment.22–26 The use of thrombolysis has decreased
in favour of anticoagulation treatment or surgery and
is nowadays mainly recommended for graft throm-
boses or in situ thromboses of native vessels of short
duration.22,27
According to most reviewers, no technique or drug
has proven superior to any other as long as the
thrombolytic agent is delivered into the throm-
bus.21,28–30 The use of high doses of thrombolytic
agents has been discouraged, mainly referring to an
increased risk for bleeding complications and
stroke.21,29 In our study, the morbidity with high-
dose thrombolysis was not discouraging and not
worse than with the low-dose treatment (Table 10).
Four major bleeding events occurred in patients with
the high-dose (7%) versus eight events (13%) with the
low-dose regimen. The mortality at 1 month was 10
and 11%, respectively. Our incidence of complications
corresponded well with the findings of a UK audit.30
The major disadvantage with high-dose thrombo-
lysis seems to be an increased risk for cerebral
haemorrhage. This may be compensated for by a
lower incidence of cardiac events than with low-dose
thrombolysis. Stroke (haemorrhagic or ischaemic)
occurred in 5% with high-dose versus 2% with low-
dose thrombolysis, whereas fatal cardiac events were
recorded in 2 and 6%, respectively (non-significant
differences). Prolonged thrombolysis is often cumber-
some and stressful for elderly patients. The time
required for restoration of blood flowwas in this study
shorter with the high-dose regimen. Two hours ofEur J Vasc Endovasc Surg Vol 31, June 2006
G. Plate et al.658treatment was sufficient to restore blood flow in 34% of
the patients and the complementary low-dose infusion
performed in the remaining patients was shorter (18 h)
than the infusion time in the patients only treated with
low-dose thrombolysis (25 h). In addition, more
frequent and extensive re-interventions were required
following low-dose thrombolysis (Table 9). The extra
stress provoked by prolonged thrombolysis and
additional interventions may be responsible for the
somewhat greater incidence of cardiac events with
low-dose thrombolysis noted in the present study and
suggested in other publications.14,15,31
Acute lower limb ischaemia is a dangerous
condition and adverse events must be expected in
this elderly population, regardless of what treatment is
employed.24,32 Thus, the risk of adverse events per se
does neither justify avoidance of low- nor high-dose
thrombolytic therapy. This concept is supported by
some communications17,19,30,33 and contradicts the bad
reputation of high-dose thrombolysis promoted by
other reviewers.21,29
The fact that most of our fatal complications
occurred in patients over the age of 75, supports the
present concept that thrombolysis should be avoided
in very old patients.24,27,30 Another relative contra-
indication to thrombolytic treatment is chronic atrial
fibrillation due to the risk of creating cardiac
embolisation. Both ischaemic strokes reported in this
study developed in patients with atrial fibrillation.
Minimal interventions (e.g. PTA or embolectomy),
lower doses of thrombolytic agents, or conservative
management may be preferential in elderly patients
and in patients with atrial fibrillation, especially in the
presence of less severe ischaemia.21,27,34 The recent UK
audit has demonstrated that good clinical results with
low complication rates can be achieved with a better
patient selection.30
The results of the present study indicate that initial
high-dose thrombolysis may provide a reduction in
the numbers and especially the magnitude of surgical
interventions required (Table 9). This contradicts the
conclusions of the Cochrane-analysis by Kessel et al.29
They did not find any reduction in adjunctive
procedures. The reason for this discrepancy is
uncertain, but could be related to variations in drugs,
doses, and techniques utilised. We used rather high
doses of thrombolytic agents and continued with a
low-dose regimen in two thirds of the patients
providing optimal clearance of thrombotic material.
All patients received adjunctive anticoagulation or
antiplatelet medication, as advocated in a consensus
document,21 and underlying lesions were corrected,
mostly with endovascular procedures, as suggested by
Ouriel.35 It is likely that residual thrombi may causeEur J Vasc Endovasc Surg Vol 31, June 2006recurrent thrombosis and ischaemia, which has
afflicted some previous studies.26 The more thorough
arterial clearance achieved with high-dose thrombo-
lysis in combination with adjunctive medication and
endovascular intervention may thus have been of
importance in reducing the need for subsequent
interventions.
We failed to demonstrate any significant difference
in primary endpoints. Our study was closed prema-
turely, mainly due to a dropout of randomising centres
and a subsequent declining enthusiasm among the
remaining centres. This may have caused a type-2
error. After 1 month, 24% of the high-dose patients and
32% of those with low-dose thrombolysis had at least
one endpoint. This is slightly less than our initial
presumption. It cannot be excluded that a larger study
would have provided a significant difference in
primary endpoints.
The two treatment groups differed somewhat in
baseline characteristics. The number of proximal (iliac)
occlusions was lower, the number of distal (popliteal
and crural) was higher, and guide-wire passage
through the entire thrombus was more often accom-
plished in the patients randomised to high-dose
thrombolysis. According to Ouriel et al.,36 thrombus
location should not affect outcome whereas guide-
wire passage through the thrombus is predictive of
success. On the other hand, positioning of the infusion
catheter within the thrombus, which was possible in
all our patients, is also very predictive of successful
thrombolysis.36 Therefore, we do not believe that the
differences in baseline characteristics were responsible
for our recorded differences in outcome.
The clinical results did not differ between the two
regimens. The long-term results were satisfactory in
both groups with an amputation-free survival of
around 85% at 1 month and 70% at 1 year. Clinical
outcome may be dependent not only on the technique
of thrombolysis but also on the effect of additional
interventions. The more frequently performed major
surgical interventions after low-dose thrombolysis
may therefore explain the lack of difference in clinical
results despite a tendency towards better patency
following high-dose thrombolysis. In other words, the
good clinical results with both regimens reflect not
only the influence of thrombolytic technique but also
the quality of overall patient care at our hospitals.
The economic relations between the two regimens
have not been thoroughly investigated in this or in any
other known study. The use of ICU- or recovery beds
was somewhat lower and the hospital stay was 1
1/2 days shorter in the high-dose group. On the other
hand, the radiology suite was occupied for about 2 h
more during the pulse-spray infusion and drug
Thrombolysis for Acute Lower Limb Ischaemia 659expenses were probably greater. Additional interven-
tions were less frequent at 1 month, which was not
sustained after 1 year. Although no detailed economic
analysis has been performed, it is likely that the lower
utilisation of hospital resources entails a reduction in
total cost with the high-dose regimen.
In summary, this study does not support a super-
iority of initial high-dose, pulse-spray thrombolysis
over low-dose infusion alone in the treatment of acute
and sub-acute ischaemia in the lower extremities. On
the other hand, this regimen does not seem to be
afflicted with more complications and may provide a
faster and more reliable restoration of limb perfusion
as well as a reduction in required re-interventions and
other utilisation of hospital resources. A larger study
would probably provide more conclusive evidence.Acknowledgements
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